A Study to Learn About the Outcomes Between Study Medicines, Enzalutamide and Darolutamide Among Men With Metastatic Castration Sensitive Prostate Cancer (mCSPC)
ACTIVE_NOT_RECRUITING
Status
Conditions
- Metastatic Castration Sensitive Prostate Cancer (mCSPC)
Interventions
- DRUG: darolutamide plus androgen deprivation therapy
- DRUG: Enzalutamide plus androgen deprivation therapy
Sponsor
Pfizer